Anastasiya М. Belozerskikh
Anastasiya М. Belozerskikh has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Bela M. Medvedeva
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications - Sergei N. Berdnikov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications - Mariia G. Lapteva
N.N. Blokhin National Medical Research Center of Oncology
2 shared publications - Mikael G. Abgaryan
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - A. B. Lukiyanchenko
N.N. Blokhin National Medical Research Center of Oncology
1 shared publication A. M. Kiseleva
N.N. Blokhin National Medical Research Center of Oncology
1 shared publication
Latest Publications
- Open Access
- 10 November 2025
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Science and Innovations in Medicine
- Vol. 10 (4) , 310-314
Possibilities of surgical treatment of pancreatic head neuroendocrine neoplasms with major venous invasion
Aim – to demonstrate the feasibility and relative safety of resection of the portal and/or superior mesenteric veins invaded by tumor during surgical treatment of the neuroendocrine neoplasm of the pancreatic head, as well as the feasibility of simultaneous resection of the liver for resectable metastases in patients with stage IV disease during primary surgery and at disease progression of any stage following surgical treatment. Material and methods. Surgical treatment of 16 patients with neuroendocrine neoplasm of the pancreatic head with invasion of the superior mesenteric and/or portal veins of stages III-IV of high and moderate differentiation (G1 and G2) included a standard gastropancreoduodenal resection in 87.5% cases, extended gastropancreoduodenal resection with aortocaval lymph node dissection in 6.25% cases, and pancreatectomy in 6.25% cases. During the standard operation, in one female patient (6.25%) segmental resection of the liver was performed to remove the metastasis. The rate of portal vein resection was 6.25%, superior mesenteric vein, 50%, both major veins, 43.8%. Neoadjuvant treatment was not administered, while adjuvant XELOX treatment was administered to 3 (18.8%) patients. The statistic processing of the study results was performed in Statistica for Windows v.10 and SPSS v21. The obtained differences were deemed statistically significant at р≤0.05 (≥95% accuracy). In order to calculate the survival rate, the Kaplan-Meier method was used with log-rank test evaluation of significance of differences. Results. The rate of R0 surgical treatment was 93.8%, the rate of complications of surgical treatment of Clavien-Dindo class III and above was 43.8% with the total rate of all complications of 75%. The main complications included gastric stasis (50.1%), arrosive hemorrhage (18.8%), acute gastrointestinal ulcer hemorrhage (18.8%), pneumonia (18.8%). The rate of postoperative thrombosis of the portal and/or superior mesenteric vein was 12.5%, leakage of the pancreato-digestive anastomosis was 12.5%, leakage of the bilio-digestive anastomosis, 6.3%, pancreatic fistula, 12.5%. Relaparotomy was performed in 2 (12.5%) patients who later died due to complications of surgical treatment (leakage of the pancreato-digestive anastomosis with arrosive hemorrhage). Disease progression was seen in 10 (62.5%) of the patients within 3 to 69.3 months, the median time before identification of progression being 39.7 [7.1; 52.8] months, and mortality from progression being 50%. Local recurrence developed in 12.5% patients, metastases in the retroperitoneal lymph nodes in 6.25%, metastases in the liver in 43.75%, in two cases, liver resection due to metastases was performed. In cases of progression, all patients received antineoplastic therapy with analogs of prolonged somatostatin. The median overall survival was 70.1 months, progression-free survival, 49.2 months, one-year survival was 81.2% and 78.6%, respectively, three-year survival, 68.2% and 63.5%, five-year, 68.2% and 36.3%, ten-year, 20.55% and 18.1%. Conclusion. The outcomes of surgical treatment of patients with neuroendocrine neoplasm of the pancreatic head with invasion of the portal and/or superior mesenteric vein show the feasibility, relative safety and efficiency of resection of these major veins. In the majority of patients, surgical treatment may be performed in the radical volume and extended by liver resection in the event of resectable metastases. Considering the relatively favorable prognosis of the disease, liver resection for resectable metastases and disease progression may be performed: it is safe, it improves quality of life of patients, and extends the period without tumor manifestations.
- 10 November 2025
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Science and Innovations in Medicine
- Vol. 10 (4) , 310-314
Open AccessPossibilities of surgical treatment of pancreatic head neuroendocrine neoplasms with major venous invasion
Aim – to demonstrate the feasibility and relative safety of resection of the portal and/or superior mesenteric veins invaded by tumor during surgical treatment of the neuroendocrine neoplasm of the pancreatic head, as well as the feasibility of simultaneous resection of the liver for resectable metastases in patients with stage IV disease during primary surgery and at disease progression of any stage following surgical treatment. Material and methods. Surgical treatment of 16 patients with neuroendocrine neoplasm of the pancreatic head with invasion of the superior mesenteric and/or portal veins of stages III-IV of high and moderate differentiation (G1 and G2) included a standard gastropancreoduodenal resection in 87.5% cases, extended gastropancreoduodenal resection with aortocaval lymph node dissection in 6.25% cases, and pancreatectomy in 6.25% cases. During the standard operation, in one female patient (6.25%) segmental resection of the liver was performed to remove the metastasis. The rate of portal vein resection was 6.25%, superior mesenteric vein, 50%, both major veins, 43.8%. Neoadjuvant treatment was not administered, while adjuvant XELOX treatment was administered to 3 (18.8%) patients. The statistic processing of the study results was performed in Statistica for Windows v.10 and SPSS v21. The obtained differences were deemed statistically significant at р≤0.05 (≥95% accuracy). In order to calculate the survival rate, the Kaplan-Meier method was used with log-rank test evaluation of significance of differences. Results. The rate of R0 surgical treatment was 93.8%, the rate of complications of surgical treatment of Clavien-Dindo class III and above was 43.8% with the total rate of all complications of 75%. The main complications included gastric stasis (50.1%), arrosive hemorrhage (18.8%), acute gastrointestinal ulcer hemorrhage (18.8%), pneumonia (18.8%). The rate of postoperative thrombosis of the portal and/or superior mesenteric vein was 12.5%, leakage of the pancreato-digestive anastomosis was 12.5%, leakage of the bilio-digestive anastomosis, 6.3%, pancreatic fistula, 12.5%. Relaparotomy was performed in 2 (12.5%) patients who later died due to complications of surgical treatment (leakage of the pancreato-digestive anastomosis with arrosive hemorrhage). Disease progression was seen in 10 (62.5%) of the patients within 3 to 69.3 months, the median time before identification of progression being 39.7 [7.1; 52.8] months, and mortality from progression being 50%. Local recurrence developed in 12.5% patients, metastases in the retroperitoneal lymph nodes in 6.25%, metastases in the liver in 43.75%, in two cases, liver resection due to metastases was performed. In cases of progression, all patients received antineoplastic therapy with analogs of prolonged somatostatin. The median overall survival was 70.1 months, progression-free survival, 49.2 months, one-year survival was 81.2% and 78.6%, respectively, three-year survival, 68.2% and 63.5%, five-year, 68.2% and 36.3%, ten-year, 20.55% and 18.1%. Conclusion. The outcomes of surgical treatment of patients with neuroendocrine neoplasm of the pancreatic head with invasion of the portal and/or superior mesenteric vein show the feasibility, relative safety and efficiency of resection of these major veins. In the majority of patients, surgical treatment may be performed in the radical volume and extended by liver resection in the event of resectable metastases. Considering the relatively favorable prognosis of the disease, liver resection for resectable metastases and disease progression may be performed: it is safe, it improves quality of life of patients, and extends the period without tumor manifestations.
- Open Access
- 23 September 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (3) , 52-63
The role of CT and MRI in assessing the degree of malignancy of neuroendocrine tumors of the pancreas
Purpose: Assessment of the diagnostic value of CT and MRI in determining the malignancy grade of pancreatic neuroendocrine tumors (NETs).Materials and methods: The study included 89 patients with pancreatic NETs. The diagnosis was established based on morphological examination after surgery or tumor biopsy. 54 patients underwent CT with contrast agent, 71 patients underwent MRI with MR contrast agent (MRCA). Based on CT and MRI data, the size, shape, structure, and signs of tumor necrosis were assessed, and quantitative indicators of density on CT and signal intensity on MRI in tumor tissue in different contrast phases were measured, and the absolute and relative percentages of contrast agent washout were calculated. Additionally, the presence of calcifications in NETs was determined using CT data, IS on T2-weighted images (WI), on diffusion-weighted images (DWI) with a b-factor of 50, 400 and 800 s/mm2 was determined using MRI data, and the value of the apparent diffusion coefficient (ADC) was measured on ADC-maps.Results: The analysis of CT and MRI data revealed that the tumor size did not depend on the degree of malignancy and did not correlate with the Ki-67 index. The number of nodes statistically significantly differed: multiple lesions were more common in Grade 1, and solitary ones in Grade 2. The shape and contours of the tumors also depended on the degree of malignancy: oval or round tumors with clear contours prevailed in Grade 1, while irregularly shaped tumors with unclear contours prevailed in Grade 3, which was accompanied by a higher Ki-67 level. Contrast agent accumulation decreased with increasing malignancy degree, especially in the arterial and venous phases according to CT data, while an inverse relationship with the Ki-67 index was observed. Contrast agent washout according to CT was significantly lower in Grade 3. No significant differences in contrast agent washout and ADC values were found in MRI, with the exception of a moderate inverse relationship between MRCA accumulation on T1-WI FS and Ki-67. MRCA accumulation and washout were inversely correlated with Ki-67.Conclusion: CT and MRI can be used to assess the grade of pancreatic NETs, improving preoperative risk stratification. The most reliable imaging markers of aggressiveness include poor margins, irregular shape, hypovascularity, severe necrosis, poor or negative washout, and decreased SI on T1-WI FS.
- 23 September 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (3) , 52-63
Open AccessThe role of CT and MRI in assessing the degree of malignancy of neuroendocrine tumors of the pancreas
Purpose: Assessment of the diagnostic value of CT and MRI in determining the malignancy grade of pancreatic neuroendocrine tumors (NETs).Materials and methods: The study included 89 patients with pancreatic NETs. The diagnosis was established based on morphological examination after surgery or tumor biopsy. 54 patients underwent CT with contrast agent, 71 patients underwent MRI with MR contrast agent (MRCA). Based on CT and MRI data, the size, shape, structure, and signs of tumor necrosis were assessed, and quantitative indicators of density on CT and signal intensity on MRI in tumor tissue in different contrast phases were measured, and the absolute and relative percentages of contrast agent washout were calculated. Additionally, the presence of calcifications in NETs was determined using CT data, IS on T2-weighted images (WI), on diffusion-weighted images (DWI) with a b-factor of 50, 400 and 800 s/mm2 was determined using MRI data, and the value of the apparent diffusion coefficient (ADC) was measured on ADC-maps.Results: The analysis of CT and MRI data revealed that the tumor size did not depend on the degree of malignancy and did not correlate with the Ki-67 index. The number of nodes statistically significantly differed: multiple lesions were more common in Grade 1, and solitary ones in Grade 2. The shape and contours of the tumors also depended on the degree of malignancy: oval or round tumors with clear contours prevailed in Grade 1, while irregularly shaped tumors with unclear contours prevailed in Grade 3, which was accompanied by a higher Ki-67 level. Contrast agent accumulation decreased with increasing malignancy degree, especially in the arterial and venous phases according to CT data, while an inverse relationship with the Ki-67 index was observed. Contrast agent washout according to CT was significantly lower in Grade 3. No significant differences in contrast agent washout and ADC values were found in MRI, with the exception of a moderate inverse relationship between MRCA accumulation on T1-WI FS and Ki-67. MRCA accumulation and washout were inversely correlated with Ki-67.Conclusion: CT and MRI can be used to assess the grade of pancreatic NETs, improving preoperative risk stratification. The most reliable imaging markers of aggressiveness include poor margins, irregular shape, hypovascularity, severe necrosis, poor or negative washout, and decreased SI on T1-WI FS.
- Open Access
- 29 June 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (2) , 73-79
Possibilities of Multiparametric Ultrasound Navigation in Biopsies of Neuroendocrine Neoplasia of the Pancreas.
Purpose: Improved biopsy results of neuroendocrine neoplasia of the pancreas and neuroendocrine neoplasia of the gastrointestinal tract of other locations under ultrasound navigation. Materials and methods: The study included 56 CT scans with intravenous contrast and clinical and laboratory methods of examining neuroendocrine neoplasia of the pancreas. The results of biopsies of neuroendocrine neoplasia of the pancreas were analyzed under ultrasound navigation in the usual B-mode and in the B-mode with complex methods for determining the elasticity of pancreatic tumors (elastometry and elastography), doppler imaging and improved visualization in B-mode. Conclusion: Additional ultrasound techniques allow us to provide qualitative and quantitative criteria for the tumor structure, which technically allows us to obtain a high-quality biopsy and avoid unnecessary biopsies.
- 29 June 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (2) , 73-79
Open AccessPossibilities of Multiparametric Ultrasound Navigation in Biopsies of Neuroendocrine Neoplasia of the Pancreas.
Purpose: Improved biopsy results of neuroendocrine neoplasia of the pancreas and neuroendocrine neoplasia of the gastrointestinal tract of other locations under ultrasound navigation. Materials and methods: The study included 56 CT scans with intravenous contrast and clinical and laboratory methods of examining neuroendocrine neoplasia of the pancreas. The results of biopsies of neuroendocrine neoplasia of the pancreas were analyzed under ultrasound navigation in the usual B-mode and in the B-mode with complex methods for determining the elasticity of pancreatic tumors (elastometry and elastography), doppler imaging and improved visualization in B-mode. Conclusion: Additional ultrasound techniques allow us to provide qualitative and quantitative criteria for the tumor structure, which technically allows us to obtain a high-quality biopsy and avoid unnecessary biopsies.
- Open Access
- 29 June 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (2) , 42-49
he first experience of using magnetic resonance spectrometry in neuroendocrine neoplasia of the pancreas.
Purpose: Improving the accuracy of pancreatic tumor detection and differential diagnosis of neuroendocrine neoplasia (NEN) with pancreatic adenocarcinomas using a two‑dimensional (2D) multivoxel hydrogen MR spectrometry protocol. Materials and methods: The study included 76 patients, including 47 cases of pancreatic tumors and 29 cases without pancreatic pathology. Pancreatic tumors were represented by 24 NEN (G1 = 4, G2 = 19, G3 = 1) and 23 adenocarcinomas. The diagnosis was established based on morphological examination after surgery or tumor biopsy. The levels of the following metabolites obtained by multivoxel MR spectrometry were determined: choline (Cho), creatine (Cr), glutamine/glutamate (Glx), N‑acetylaspartate (NAA), lactate (Lac) and their ratios Cho/Cr, Lac/Cr, Cho/NAA, Glx/Cr. Results: The results of the study showed a higher level of creatine in unchanged tissue compared to pancreatic tumors (p = 0.032): in unchanged pancreatic tissue — from 6.01 to 23 (median 12.4), in tumors — from 3.04 to 13.55. (median 6.01). At a threshold signal level from creatine of less than 16.1, the sensitivity in detecting pancreatic tumor was 70.9 %, specificity — 61.9 %. The Cho/Cr level was higher in tumors compared to unchanged pancreatic tissue (p = 0.031). It was also found that the presence of glutamate and glutamine in the tumor, recorded by MR spectrometry data, is more common in NEN compared to pancreatic adenocarcinomas (p = 0.029): the presence of glutamate and glutamine was noted in 66.7 % of NEN and in 34.8 % of pancreatic adenocarcinomas. The Glx/Cr level in NEN was also higher compared to adenocarcinomas (p = 0.026). Conclusion: MR spectrometry may be a useful adjunctive tool in the detection of pancreatic tumors and differential diagnosis of pancreatic adenocarcinomas and NENs, to improve the accuracy of pancreatic tumor detection and differential diagnosis of NENs with pancreatic adenocarcinomas using a two‑dimensional (2D) multivoxel 1H‑magnetic resonance spectrometry (MRS) protocol.
- 29 June 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (2) , 42-49
Open Accesshe first experience of using magnetic resonance spectrometry in neuroendocrine neoplasia of the pancreas.
Purpose: Improving the accuracy of pancreatic tumor detection and differential diagnosis of neuroendocrine neoplasia (NEN) with pancreatic adenocarcinomas using a two‑dimensional (2D) multivoxel hydrogen MR spectrometry protocol. Materials and methods: The study included 76 patients, including 47 cases of pancreatic tumors and 29 cases without pancreatic pathology. Pancreatic tumors were represented by 24 NEN (G1 = 4, G2 = 19, G3 = 1) and 23 adenocarcinomas. The diagnosis was established based on morphological examination after surgery or tumor biopsy. The levels of the following metabolites obtained by multivoxel MR spectrometry were determined: choline (Cho), creatine (Cr), glutamine/glutamate (Glx), N‑acetylaspartate (NAA), lactate (Lac) and their ratios Cho/Cr, Lac/Cr, Cho/NAA, Glx/Cr. Results: The results of the study showed a higher level of creatine in unchanged tissue compared to pancreatic tumors (p = 0.032): in unchanged pancreatic tissue — from 6.01 to 23 (median 12.4), in tumors — from 3.04 to 13.55. (median 6.01). At a threshold signal level from creatine of less than 16.1, the sensitivity in detecting pancreatic tumor was 70.9 %, specificity — 61.9 %. The Cho/Cr level was higher in tumors compared to unchanged pancreatic tissue (p = 0.031). It was also found that the presence of glutamate and glutamine in the tumor, recorded by MR spectrometry data, is more common in NEN compared to pancreatic adenocarcinomas (p = 0.029): the presence of glutamate and glutamine was noted in 66.7 % of NEN and in 34.8 % of pancreatic adenocarcinomas. The Glx/Cr level in NEN was also higher compared to adenocarcinomas (p = 0.026). Conclusion: MR spectrometry may be a useful adjunctive tool in the detection of pancreatic tumors and differential diagnosis of pancreatic adenocarcinomas and NENs, to improve the accuracy of pancreatic tumor detection and differential diagnosis of NENs with pancreatic adenocarcinomas using a two‑dimensional (2D) multivoxel 1H‑magnetic resonance spectrometry (MRS) protocol.
- Open Access
- 17 December 2023
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 6 (4) , 93-98
Rare Manifestation of Neuroendocrine Pancreatic Tumor: Difficulties of Diagnosis
A rare case of neuroendocrine pancreatic tumor is presented. The clinical, CT/MRI and morphological manifestations of the tumor are described. Some differential diagnosis’ problems among a spectrum of pancreatic tumor and tumor-like cystic lesions are being discussed.
- 17 December 2023
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 6 (4) , 93-98
Open AccessRare Manifestation of Neuroendocrine Pancreatic Tumor: Difficulties of Diagnosis
A rare case of neuroendocrine pancreatic tumor is presented. The clinical, CT/MRI and morphological manifestations of the tumor are described. Some differential diagnosis’ problems among a spectrum of pancreatic tumor and tumor-like cystic lesions are being discussed.